ClinicalTrials.gg
CompletedNCT02137759Updated Oct 30, 2026Results posted

MRSI to Predict Response to RT/TMZ ± Belinostat in GBM

A Phase 2 interventional study of Standard Radiation Therapy and Standard Temozolomide in Glioblastoma Multiforme of Brain, sponsored by Emory University. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Emory University · Phase 2, Interventional, and Treatment

How we know

Updated Oct 30, 2026Now CompletedResults posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Glioblastoma by Emory University — none open to participants now, 1 under way, none of them phase 3. Glioblastoma · Emory University.

Enrollment
3rd of 11
29 · median 12
Started
2014
with 1 other
Phase 2
5 of 12
none open now
Registered
5th of 12
by date

Among the 12 studies in Glioblastoma by Emory University, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2014, is one of 5 in phase 2, and was the 5th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

None of the 12 studies in Glioblastoma by Emory University is open now. The open studies under Glioblastoma, anywhere →

Where they have run

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Glioblastoma by Emory University as a file.
02

Study summary

In the first phase of this study (Cohort 1), the investigators will determine the feasibility of adding MRSI to the evaluation of newly-diagnosed GBM patients treated with standard RT/TMZ and determine whether magnetic resonance spectroscopic imaging (MRSI) can predict for better outcomes in these patients. In the second phase of this study (Cohorts 2a and 2b), the investigators will find the maximum tolerated dose of belinostat for treating newly-diagnosed GBM patients with standard RT/TMZ and will determine whether MRSI can aid clinicians in the early determination of response to this new therapy.

Read the detailed description

Patients will be assigned to Cohort 1 (standard RT/TMZ) followed by entry to either Cohort 1 or Cohort 2a (standard RT/TMZ + dose finding for belinostat), followed by assignment to Cohort 2b (standard RT/TMZ + tolerable dose of belinostat).

Patients will undergo MRSI scans before beginning treatment and then at several time points during treatment to look for the early response of their tumor to treatment. Blood and tumor samples will be used to measure the levels of certain markers within the cancer cells. Patients will also be assessed for the side effects they experience. Progression-free and overall survival outcomes will be recorded. Patients will also have assessment of their depressive symptoms, quality-of-life and neurocognitive function at several time points during and after therapy course.

03

Conditions studied

  • Glioblastoma Multiforme of Brain

Browse trials for

Keywords

  • Glioblastoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly-diagnosed glioblastoma or gliosarcoma that has been confirmed pathologically
  • ≥ 18 years of age
  • Able to have MRI scans
  • Measurable contrast-enhancing supratentorial tumor (≥ 0.2 cc (current resolution of MRSI is 0.108cc)) in a region amenable to MRSI
  • Have the following lab values ≤ 14 days prior to registration:

    • white blood cell count ≥ 3,000/μL
    • ≥ 1,500/μL
    • count of ≥ 100,000/μL
    • ≥ 10 gm/dL (transfusion is allowed to reach minimum level)
    • serum glutamic-oxaloacetic transaminase () ≤ 2.0x upper normal limit (UNL)
    • ≤ 2 x UNL
    • creatinine ≤ 1.5 mg/dL
  • of ≥ 12 weeks
  • Performance Score ≥ 60
  • Women of must have a negative beta-human chorionic gonadotropin pregnancy test documented ≤ 7 days prior to registration
  • All men and women of childbearing potential must agree to use adequate barrier for the duration of study participation and for 12 weeks after the last dose of study drug (If pregnancy or suspected pregnancy occur while participating in study, treating physician should be informed immediately)
  • Understand and provide written
  • Both men and women, and members of all races and ethnic groups are eligible for this trial (Subjects will be approximately representative of the demographics of the referral base for the participating institutions)
  • Able to swallow capsules
  • Willing to provide mandatory tissue samples (unstained slides) for research purposes
  • Willing to forego other cytotoxic and non-cytotoxic therapies against the tumor while being treated on this protocol

Exclusion criteria

Exclusion Criteria:

  • Pacemakers, non-titanium aneurysm clips, neurostimulators, cochlear implants, non-titanium metal in ocular structures, history of being a steel worker, or other incompatible implants which makes MRI safety an issue
  • Any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy
  • History of any other invasive cancer (except non-melanoma skin cancer and excluding carcinoma in-situ), unless in complete remission and off of all therapy for that disease for ≥ 3 years, are ineligible
  • Active infection or serious intercurrent medical illness
  • Any disease that will obscure toxicity or dangerously alter drug metabolism
  • Receiving any other agents
  • Received prior cytotoxic, non-cytotoxic or experimental drug therapies for brain tumor
  • History of prior cranial radiation
  • History of myocardial infarction or unstable angina ≤ 6 months prior to registration or congestive heart failure (CHF) requiring use of ongoing maintenance therapy, or life-threatening ventricular arrhythmias
  • Patients with congenital long syndrome (for cohorts 2a and 2b [belinostat cohorts] only, not required for cohort 1)
  • Has prolonged corrected QT (QTc) interval (> 450 msec) (for cohorts 2a and 2b [belinostat cohorts] only, ECG not required for cohort 1)
  • Taking any of the following Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes ≤ 7 days prior to registration (for cohorts 2a and 2b [belinostat cohorts] only)

    • Quinidine, procainamide, disopyramide
    • Amiodarone, sotalol, ibutilide, dofetilide
    • Erythromycin, clarithromycin
    • Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide
    • Cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine
  • Taking valproic acid ≤ 2 weeks prior to initiation of belinostat therapy (for cohorts 2a and 2b [belinostat cohorts] only)
  • Residual enhancing tumor that lies completely within 1-2 cm of the inner table of the skull (Please consult study neuroradiologist or study PIs at your site if there is uncertainty regarding this exclusion criteria)
  • May not be enrolled on any other therapeutic trial for which they are receiving an anti-tumor therapy. (Note: patients on the standard therapy arm of another GBM trial that otherwise meet eligibility requirements for this trial remain eligible for cohort 1)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Active comparator
    Std RT/TMZ (Cohort 1)

    * Standard radiation therapy * Standard temozolomide

    Radiation: Standard Radiation Therapy · Drug: Standard Temozolomide

  • Experimental
    Std RT/TMZ + belinostat (Cohorts 2a, 2b)

    * Standard radiation therapy * Standard temozolomide * Belinostat

    Radiation: Standard Radiation Therapy · Drug: Standard Temozolomide · Drug: Belinostat

Interventions

  • RadiationStandard Radiation Therapy

    Radiation therapy to 60 Gy

  • DrugTemozolomideStudies of TemozolomideTemozolomide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Temozolomide given orally

    Also known as: Temodar

  • Belinostat dose to be determined, given intravenously over 30-45 minutes

    Also known as: Beleodaq, PXD101

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    The investigators will use a support vector machine approach to determine an MRSI 5-metabolite profile at week 3 in Cohort 1 that is predictive of prolonged PFS at 9 months.

    Time frame: From date of registration to date of progression or death

  2. Maximum Tolerated Dose of Belinostat (Cohort 2a)

    The investigators will determine the maximum tolerated dose of belinostat (up to 1000 mg/day x 5 days q3weeks x 3) used with standard RT/temozolomide for newly diagnosed GBM patients.

    Time frame: 9 weeks

Secondary outcomes

  1. Median Overall Survival

    Overall survival was defined as the time from the date of surgery until death from any cause. Participants who were alive or lost to follow-up were censored at their last known follow-up. Median overall survival was estimated using the Kaplan-Meier method.

    Time frame: From the date of surgery until death or last known follow-up; median follow-up was 50 months.

  2. Progression Free Survival

    The investigators will determine whether changes in MRSI metabolite maps at day 8 (for Cohort 2 only) and week 11 (for Cohort 1 and 2) predict for PFS at 9 months.

    Time frame: From date of registration to date of progression or death

07

Results

Posted Oct 30, 2026

Participant flow

Participant flow — Overall Study
MilestoneStd RT/TMZ (Cohort 1)Std RT/TMZ + Belinostat (Cohorts 2a)Std RT/TMZ + Belinostat (Cohort 2b)
Started14410
Completed1349
Not completed101

Outcome measures

PrimaryProgression Free Survival (PFS)

The investigators will use a support vector machine approach to determine an MRSI 5-metabolite profile at week 3 in Cohort 1 that is predictive of prolonged PFS at 9 months.

Time frame:
From date of registration to date of progression or death
Reported as:
Median · months
Progression Free Survival (PFS)
monthsStd RT/TMZ (Cohort 1)Std RT/TMZ + Belinostat (Cohorts 2a)Std RT/TMZ + Belinostat (Cohorts 2b)
Progression Free Survival (PFS)9.0 (2.9 to 45.4)8.4 (3.3 to 42.3)11.2 (3.3 to 19.3)
PrimaryMaximum Tolerated Dose of Belinostat (Cohort 2a)

The investigators will determine the maximum tolerated dose of belinostat (up to 1000 mg/day x 5 days q3weeks x 3) used with standard RT/temozolomide for newly diagnosed GBM patients.

Time frame:
9 weeks
Reported as:
Number · mg
Maximum Tolerated Dose of Belinostat (Cohort 2a)
mgActive Comparator: Std RT/TMZ (Cohort 1)Std RT/TMZ + Belinostat (Cohorts 2a & 2b)
Maximum Tolerated Dose of Belinostat (Cohort 2a)0500
SecondaryMedian Overall Survival

Overall survival was defined as the time from the date of surgery until death from any cause. Participants who were alive or lost to follow-up were censored at their last known follow-up. Median overall survival was estimated using the Kaplan-Meier method.

Time frame:
From the date of surgery until death or last known follow-up; median follow-up was 50 months.
Reported as:
Median · months
Median Overall Survival
monthsStd RT/TMZ (Cohort 1)Std RT/TMZ + Belinostat (Cohorts 2a)Std RT/TMZ + Belinostat (Cohort 2b)
Median Overall Survival15.8 (5.9 to 62.2)18.5 (7.4 to 49.3)20.5 (9.4 to 41.4)
SecondaryProgression Free Survival

The investigators will determine whether changes in MRSI metabolite maps at day 8 (for Cohort 2 only) and week 11 (for Cohort 1 and 2) predict for PFS at 9 months.

Time frame:
From date of registration to date of progression or death
Reported as:
Median · months
Progression Free Survival
monthsStd RT/TMZ (Cohort 1)Std RT/TMZ + Belinostat (Cohort 2a)Std RT/TMZ + Belinostat (Cohorts 2b)
Progression Free Survival9.0 (2.9 to 45.4)8.4 (3.3 to 42.3)11.2 (3.3 to 19.3)

Adverse events

Collected over All-Cause Mortality was assessed through study completion, up to 6 years; all adverse events were collected through 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Std RT/TMZ (Cohort 1)0/13 (0%)0/13 (0%)12/13 (92.3%)
Std RT/TMZ + Belinostat (Cohort 2a)0/4 (0%)2/4 (50%)3/4 (75%)
Std RT/TMZ + Belinostat (Cohort 2b)0/9 (0%)6/9 (66.7%)2/9 (22.2%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventStd RT/TMZ (Cohort 1)Std RT/TMZ + Belinostat (Cohort 2a)Std RT/TMZ + Belinostat (Cohort 2b)
ThrombocytopeniaInvestigations0/132/40/9
HeadacheNervous system disorders0/130/43/9
NeutropeniaInvestigations0/131/40/9
Wound infectionInfections and infestations0/131/40/9
SeizureNervous system disorders0/130/41/9
AgitationPsychiatric disorders0/130/41/9
AnxietyPsychiatric disorders0/130/41/9
ConfusionPsychiatric disorders0/130/41/9
PsychosisPsychiatric disorders0/130/41/9
PalpitationsCardiac disorders0/130/41/9
Most frequent other events
Most frequent other events
EventStd RT/TMZ (Cohort 1)Std RT/TMZ + Belinostat (Cohort 2a)Std RT/TMZ + Belinostat (Cohort 2b)
AgitationPsychiatric disorders10/130/40/9
ConfusionPsychiatric disorders10/131/40/9
Psychiatric disordersPsychiatric disorders3/132/40/9
InsomniaPsychiatric disorders5/130/42/9
AnxietyPsychiatric disorders3/131/40/9
DepressionPsychiatric disorders3/130/40/9

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Std RT/TMZ (Cohort 1)Std RT/TMZ + Belinostat (Cohorts 2a)Std RT/TMZ + Belinostat (Cohorts 2b)Total
<=18 years0000
Between 18 and 65 years104721
>=65 years3025
Age, Continuous
Age, Continuous(years)Std RT/TMZ (Cohort 1)Std RT/TMZ + Belinostat (Cohorts 2a)Std RT/TMZ + Belinostat (Cohorts 2b)Total
Mean58.5 ± 11.151.0 ± 5.851.3 ± 14.454.85 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Std RT/TMZ (Cohort 1)Std RT/TMZ + Belinostat (Cohorts 2a)Std RT/TMZ + Belinostat (Cohorts 2b)Total
Female62412
Male72514
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Std RT/TMZ (Cohort 1)Std RT/TMZ + Belinostat (Cohorts 2a)Std RT/TMZ + Belinostat (Cohorts 2b)Total
Hispanic or Latino0000
Not Hispanic or Latino134926
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Std RT/TMZ (Cohort 1)Std RT/TMZ + Belinostat (Cohorts 2a)Std RT/TMZ + Belinostat (Cohorts 2b)Total
American Indian or Alaska Native0000
Asian1001
Native Hawaiian or Other Pacific Islander0000
Black or African American1012
White114823
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Std RT/TMZ (Cohort 1)Std RT/TMZ + Belinostat (Cohorts 2a)Std RT/TMZ + Belinostat (Cohorts 2b)Total
United States134926
08

Study locations

2 sites
  • Emory University/Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21287, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Mar 2019, 58 months.

Results were first posted in Oct 2026, 7 years 7 months after primary completion.

Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 58 months is close to that.

Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Aug 2023 → Mar 2019 and completion Aug 2024 → Jan 2022.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2014
First posted
May 14, 2014
StartActual
May 7, 2014
Primary completionActual
Mar 25, 2019was Aug 2023
CompletionActual
Jan 24, 2022was Aug 2024
Results first posted
Oct 30, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 30, 2026
Results
Results posted
posted Oct 30, 2026
Primary completion
Aug 15, 2023→Mar 25, 2019 (actual)
Oct 30, 2026
Study completion
Aug 15, 2024→Jan 24, 2022 (actual)
Oct 30, 2026
Primary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedProgression Free Survival (PFS) (Cohort 1)Time frame: 9 months → From date of registration to date of progression or death
  • RemovedProgression Free Survival (PFS) (Cohort 2b)Time frame: 9 months
Oct 30, 2026
Documents
Secondary outcomes
1 edited, 1 time frame changed, 3 removed
What changed in the outcomes
  • EditedMedian Overall SurvivalTime frame: 18 months → From the date of surgery until death or last known follow-up; median follow-up was 50 months.
  • RemovedIDS-SR score changeTime frame: 11 weeks
  • Time frameProgression Free Survival9 months → From date of registration to date of progression or death
  • Removedother outcomeQOL changesTime frame: up to 2 years
  • Removedother outcomeNeurocognitive function changesTime frame: up to 2 years
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Active, not recruiting→Completed
    Results posted
    Primary completion Aug 15, 2023→Mar 25, 2019 (now actual)
    Study completion Aug 15, 2024→Jan 24, 2022 (now actual)
    Primary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedProgression Free Survival (PFS) (Cohort 1)Time frame: 9 months → From date of registration to date of progression or death
    • RemovedProgression Free Survival (PFS) (Cohort 2b)Time frame: 9 months
    Secondary outcomes 1 edited, 1 time frame changed, 3 removed
    What changed in the outcomes
    • EditedMedian Overall SurvivalTime frame: 18 months → From the date of surgery until death or last known follow-up; median follow-up was 50 months.
    • RemovedIDS-SR score changeTime frame: 11 weeks
    • Time frameProgression Free Survival9 months → From date of registration to date of progression or death
    • Removedother outcomeQOL changesTime frame: up to 2 years
    • Removedother outcomeNeurocognitive function changesTime frame: up to 2 years
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02137759
Lead sponsor
Emory University
Responsible party
Hui-Kuo Shu (Principal Investigator, Emory University) — Principal investigator
First posted
May 14, 2014
Start date
May 7, 2014
Primary completion
Mar 25, 2019
Completion
Jan 24, 2022
Results posted
Oct 30, 2026
Last update
Oct 30, 2026

Study contacts

Hui-Kuo Shu, MD, PhD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belinostat

Start the discussion